EURneffy®: Revolutionizing Anaphylaxis Treatment in Europe
Revolutionary Launch of EURneffy® in Europe
ALK today heralded a significant advancement in emergency medicine with the market launch of EURneffy® 2 mg in Germany. This innovative product is the first nasal spray designed to deliver adrenaline for the emergency treatment of anaphylaxis, a severe allergic reaction that can be life-threatening. This product is particularly crucial for adults and children weighing over 30 kg who may face such urgent medical situations.
Features and Benefits of EURneffy®
What sets EURneffy® apart is its user-friendly, needle-free design, which empowers individuals to administer adrenaline confidently when it is most critical. The ease of use aims to eliminate the fear and hesitation often felt with traditional auto-injectors, enhancing the overall efficiency of emergency treatment. Additionally, EURneffy® boasts a shelf life of 30 months and superior temperature stability, ensuring its effectiveness over extended periods compared to other available adrenaline auto-injectors.
Testimonial from ALK Executives
Flora Beiche-Scholz, ALK's Senior Vice President of Commercial Operations in Europe, expressed her enthusiasm: "With the launch of EURneffy®, healthcare providers in Germany have access to a pioneering, easy-to-carry adrenaline treatment option for their patients with life-threatening allergies. We believe this innovation will profoundly improve the lives of those dealing with severe allergic reactions, encouraging consistent carrying of emergency medication among patients and caregivers alike."
Robust Clinical Data Supporting Approval
The European approval for EURneffy® was granted after a comprehensive evaluation of data from its development program, which involved over 700 participants. Importantly, no severe adverse events were reported throughout the clinical studies. The clinical pharmacological data showcased the safety and efficacy of EURneffy® 2 mg, indicating comparable pharmacodynamics and pharmacokinetics to traditional auto-injectors. Moreover, a 1 mg dosage of EURneffy® intended for children weighing between 15-30 kg is currently undergoing regulatory review in the EU, anticipated for completion in the coming years.
Anaphylaxis: A Pressing Health Concern
Anaphylaxis is not a rare condition; in Europe, it affects up to eight individuals per 100,000 each year. It's estimated that one in every 300 individuals will experience anaphylaxis at some point in their lives. This underscores the importance of rapid access to effective treatments during emergencies. Unfortunately, many individuals at risk may feel uncertain or hesitant when faced with using larger auto-injectors, highlighting a clear need for products like EURneffy®.
Strategic Licensing and Future Collaborations
In a noteworthy strategic move, ALK recently entered into a licensing agreement with ARS Pharmaceuticals, Inc. This agreement grants ALK exclusive global rights to commercialize neffy® and EURneffy® in Europe, excluding specific territories like the USA, Australia, New Zealand, Japan, and China. In a further development, the partnership has now expanded to include a co-promotion deal in the United States.
The introduction of EURneffy® will not influence ALK’s financial projections for the upcoming years, ensuring that the company remains on track with its business commitments and goals.
Contact Information for Media Inquiries
ALK encourages any inquiries regarding EURneffy® to be directed to their media relations team. For investor relations, please contact Per Plotnikof at +45 4574 7527 or +45 2261 2525. For media inquiries, reach out to Maiken Riise Andersen at +45 5054 1434.
About ALK
ALK is a renowned global specialty pharmaceutical firm based in Hørsholm, Denmark, dedicated to developing treatments for allergy and allergic asthma. The company focuses on allergy immunotherapy (AIT) treatments and offers a variety of products and services tailored to allergy sufferers and healthcare professionals. With a workforce of approximately 2,800 employees and a presence in numerous countries, ALK is committed to enhancing the quality of life for individuals dealing with allergies.
Frequently Asked Questions
What is EURneffy®?
EURneffy® is an innovative nasal spray designed to deliver adrenaline for the emergency treatment of anaphylaxis, suitable for adults and children over 30 kg.
How does EURneffy® work?
EURneffy® works by delivering adrenaline through a needle-free design, allowing for quick and effective treatment during allergic emergencies.
What are the advantages of EURneffy® over traditional auto-injectors?
EURneffy® has a longer shelf life, improved temperature stability, and is user-friendly, making it easier for individuals to administer in emergencies.
What safety data supports EURneffy®?
Clinical studies involving over 700 participants reported no serious adverse events, showing that EURneffy® is a safe and effective option for treating anaphylaxis.
How can I contact ALK for more information?
For questions related to EURneffy®, inquiries can be addressed to Per Plotnikof at +45 4574 7527 or Maiken Riise Andersen at +45 5054 1434 for media inquiries.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.